Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma

Dupilumab treatment versus placebo improved exacerbation rate and lung function outcomes in patients with uncontrolled moderate-to-severe asthma and high type 2 biomarkers at baseline, regardless of baseline characteristics in the phase 3 QUEST study https://bit.ly/3yR7MlD

Detalles Bibliográficos
Autores principales: Busse, William W., Paggiaro, Pierluigi, Muñoz, Xavier, Casale, Thomas B., Castro, Mario, Canonica, G. Walter, Douglass, Jo A., Tohda, Yuji, Daizadeh, Nadia, Ortiz, Benjamin, Pandit-Abid, Nami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522685/
https://www.ncbi.nlm.nih.gov/pubmed/34326187
http://dx.doi.org/10.1183/13993003.04605-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522685/
https://www.ncbi.nlm.nih.gov/pubmed/34326187
http://dx.doi.org/10.1183/13993003.04605-2020

Ejemplares similares